Citation
- Authors: Weiss, A., Neuberg, P., Philippot, S., Erbacher, P., Weill, C. O.
- Year: 2011
- Journal: Biotechnol Bioeng
- Applications: in vitro / Protein/Peptide/Antibody / PULSin
- Cell types:
- Name: A549
Description: Human lung carcinoma cells, type II pneumocytes
Known as: A-549 - Name: CHO
Description: Chinese hamster ovary cells - Name: HEK-293
Description: Human embryonic kidney Fibroblast
Known as: HEK293, 293 - Name: Hep G2
Description: Human hepatocarcinoma cells - Name: Jurkat
Description: Human acute T cell leukemia line - Name: MCF7
Description: Human breast adenocarcinoma cells
Known as: MCF-7, MCF 7 - Name: NIH/3T3
Description: Murine embryonic fibroblasts
Known as: NIH/3T3, 3T3 - Name: PC-3
Description: Human prostate carcinoma cells
Known as: PC3, PC 3 - Name: Rat primary neurons
- Name: SiHa
Description: Human cervix squamous carcinoma cells - Name: THP-1
Description: Human acute monocytic leukaemia cells
Known as: THP1, THP 1
- Name: A549
Abstract
Peptides, highly diverse by their nature, are important biochemical and pharmaceutical tools: ligands for cellular receptors, transcription factors, immuno-suppressants, vaccines, etc. As the majority of their targets are intracellular, peptides need to cross the plasma membrane and gain access to the cytoplasm. However, due to their physicochemical properties, most peptides need to be entrapped by a molecular vehicle to be able to reach the cytosol compartment. In this paper we present new biological tools to enhance intracellular peptides delivery. Based on electrostatic interactions, two complementary types of amphiphilic molecules have been designed as delivery vehicles. A diverse set of fluorescently labeled peptides have successfully been delivered. This opens the avenue for the use of peptides combined to delivery vehicles as therapeutic aids. Biotechnol. Bioeng. (c) 2011 Wiley Periodicals, Inc.